LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com . LEO Pharma Canada is located in Toronto, Ontario.

To learn more about CHE, visit www.TalkCHE.com. LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with ...

No such med has yet been approved in the U.S.—limiting derms to prescribe only general eczema treatments for CHE, which is a distinct condition from eczema—though Leo’s delgocitinib cream, a ...

preparing them to lead LEO Pharma through the next stage of the climb🏔 The past three years of our transformation journey have shown the tremendous potential of our organization, and we are ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

The Pharma CI Europe Conference & Exhibition (April 23-24, 2025) is the industry's gold standard event for senior level pharma, biotech, and medical device professionals who seek the latest in ...

In collaboration with LA County's Justice Care and Opportunities Department our outdoor resource fair features networking opportunities, workshops, and exhibition booths from a range of local ...